Effect of essential hypertension on cardiac autonomic function in type 2 diabetic patients
Naohiko Takahashi, MD*,
Mikiko Nakagawa, MD ,
Tetsunori Saikawa, MD ,
Tatsuhiko Ooie, MD*,
Kunio Yufu, MD*,
Sakuji Shigematsu, MD*,
Masahide Hara, MD*,
Hiroshi Sakino, MD*,
Isao Katsuragi, MD*,
Toshimitsu Okeda, MD*,
Hironobu Yoshimatsu, MD* and
Toshiie Sakata, MD*
* Department of Internal Medicine I, School of Medicine, Oita Medical University, Oita, Japan
Department of Laboratory Medicine, School of Medicine, Oita Medical University, Oita, Japan

View larger version (28K):
[in a new window]
|
Figure 1 Comparison of measurements of autonomic function tests between hypertensive diabetic (HD) and normotensive diabetic (ND) patients. (A) Baroreflex sensitivity (BRS). (B) Plasma norepinephrine (NE) concentration. (C) Heart rate variability (HRV). Power of high-frequency component ([HF] 0.15 to 0.40 Hz, a) and the ratio of the low-frequency power ([LF] 0.04 to 0.15 Hz) to HF power ([LF/HF] b). Values of HRV were transformed using a natural logarithm because their distributions were skewed. (D) Cardiac 123I-metaiodobenzylguanidine (MIBG) scintigraphic findings. Myocardial uptake of 123I-MIBG at early (a) and delayed (b) phases. Myocardial uptake of 123I-MIBG is expressed as the mean heart-to-mediastinum (H/M) ratio. (c) Percent washout rate (WR) of 123I-MIBG. Data are mean ± SD. *p < 0.05; **p < 0.01. ns = not significant.
|
|
|